News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Synergy Pharmaceuticals and Fox Chase Cancer Center Presentation at 2011 American College of Gastroenterology Meeting Highlights Potential of GC-C Agonists to Delay Progression of Colitis into Colon Cancer


10/31/2011 7:10:40 AM

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc. (OTC QB: SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that poster P409 presented at the upcoming 2011 annual scientific meeting of the American College of Gastroenterology highlights the potential use of guanylate cyclase-C agonists to delay progression of colitis into colon cancer. Poster P409 was selected as an “ACG Presidential Award Winning Poster”, a recognition given to the most highly ranked abstracts selected for poster sessions in each category. The work reported in poster P409 was a collaborative effort between Synergy scientists and the scientists from Fox Chase Cancer Center, Philadelphia, Drs. Margie Clapper, Wen-Chi Chang and Harry Cooper.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES